Business
Update: Enovis Announces Fourth Quarter and Full Year 2025 Results
Continued commercial momentum with full year 2025 sales growth of 7% on a reported basis and 6% organically Full year 2025 Reconstructive sales grew 10% Y/Y on a reported basis and 8% on an organic basis Full year 2025 Prevention & Recovery sales grew 4% Y/Y on a reported and organic basis Dallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full yea
About this update from Enovis Corporation
[{"type":"image","alt":"Enovis Corporation","displaySize":"","headline":null,"caption":"Enovis Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":73,"url":"https://media.zenfs.com/en/globenewswire.com/04c85b7575377030906937c34935ae92"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qc6jvQoTNwKdaM8z5d_s_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/04c85b7575377030906937c34935ae92","width":300,"height":73}},"lazy":false},{"type":"text","content":"","length":0,"tagName":"p","attribs":{}},{"type":"text","content":"","length":0,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Continued commercial momentum with full year 2025 sales growth of 7% on a reported basis and 6% organically ","length":112,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":112,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Full year 2025 Reconstructive sales grew 10% Y/Y on a reported basis and 8% on an organic basis","length":95,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":95,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Full year 2025 Prevention & Recovery sales grew 4% Y/Y on a reported and organic basis","length":90,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":90,"olType":false},{"type":"text","content":"Dallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.","length":348,"tagName":"p"},{"type":"text","content":"Fourth Quarter 2025 Financial Results","length":37,"tagName":"p"},{"type":"text","content":"Enovis’ fourth-quarter net sales of $576 million grew 3% on a reported basis and 2% on an organic basis from the same quarter in 2024. Fourth-quarter results reflect growth in Global Reconstructive and stable execution in Prevention & Recovery. Compared to the same quarter in 2024, net sales in Recon grew 7% on a reported basis, with 3% organic sales growth, and net sales in P&R declined 1% on a reported basis and were flat on an organic basis.","leng...